The European Medicines Agency (EMA)
Pharmacovigilance Risk Assessment Committee (PRAC) has started a review of drug induced
liver injury potentially related to Esmya (ulipristal acetate). The review started due to four
reports of serious liver injury, occurred since 2012; the date of the EU marketing authorization,
three of which ended in liver transplantation, in patients treated with the medicine.